Evidence map›Paper›PMID 37252616›Full record

ArticleWellcome open research2022

LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis.

Charles Lacey, Ahmed Musa, El Tahir Khalil, Brima Younis, Mohamed Osman, Rebecca Wiggins, Ada Keding, Paul Kaye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Wellcome open research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Evaluation ofMicrobiology spectrum · 2025
    Article
  3. An Update on Clinical and Pathogenic Spectra of Leishmaniasis.Expert reviews in molecular medicine · 2025
    Review
  4. Review
  5. Advances inPathogens (Basel, Switzerland) · 2024
    Review
  6. Article
  7. An update on recombinant vaccines against leishmaniasis.The Indian journal of medical research · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Charles LaceyYork Biomedical Research Institute, University of York, UK, York, UK.ORCID https://orcid.org/0000-0001-9250-2638
Ahmed MusaInstitute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
El Tahir KhalilInstitute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
Brima YounisInstitute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
Mohamed OsmanYork Biomedical Research Institute, University of York, UK, York, UK.
Rebecca WigginsYork Biomedical Research Institute, University of York, UK, York, UK.
Ada KedingYork Trials Unit, University of York, UK, York, UK.
Paul KayeYork Biomedical Research Institute, University of York, UK, York, UK.ORCID https://orcid.org/0000-0002-8796-4755
University of York · GBUniversity of Khartoum · SD

Funding

Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LeishmaniaPKDLRCTSudan

Identifiers

PMID37252616
PMCPMC10213822
OpenAlexW4289549960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.